NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today the appointment of Frida Grynspan, Ph.D., to Vice President of Research and Development, effective March 1, 2009. Dr. Grynspan will report directly to Zami Aberman, Chairman, President and CEO of Pluristem.
